Biocept (BIOC) Set to Announce Earnings on Tuesday

Share on StockTwits

Biocept (NASDAQ:BIOC) is scheduled to be releasing its earnings data after the market closes on Tuesday, August 14th. Analysts expect Biocept to post earnings of ($3.30) per share for the quarter.

Biocept (NASDAQ:BIOC) last announced its earnings results on Tuesday, May 15th. The medical research company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.03). Biocept had a negative net margin of 561.47% and a negative return on equity of 445.14%. The company had revenue of $0.81 million for the quarter, compared to analysts’ expectations of $1.21 million. On average, analysts expect Biocept to post $-9 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Shares of Biocept opened at $4.02 on Monday, according to Marketbeat. Biocept has a 12 month low of $3.50 and a 12 month high of $44.10. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.31 and a current ratio of 2.41.

Several brokerages have recently commented on BIOC. Zacks Investment Research downgraded Biocept from a “hold” rating to a “sell” rating in a report on Wednesday, July 25th. ValuEngine downgraded Biocept from a “buy” rating to a “hold” rating in a report on Thursday, August 2nd. Finally, Westpark Capital downgraded Biocept from an “outperform” rating to a “hold” rating in a report on Wednesday, May 23rd.

Biocept Company Profile

Biocept, Inc, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms.

Featured Article: Leveraged Buyout (LBO) Explained

Earnings History for Biocept (NASDAQ:BIOC)

Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with's FREE daily email newsletter.

Leave a Reply